4//SEC Filing
NEWLINK GENETICS CORP 4
Accession 0001126234-15-000065
CIK 0001126234operating
Filed
Apr 2, 8:00 PM ET
Accepted
Apr 3, 5:29 PM ET
Size
19.1 KB
Accession
0001126234-15-000065
Insider Transaction Report
Form 4
NEWLINK GENETICS CORP(NLNK)
Ramsey William J.
Quality Assurance Officer
Transactions
- Sale
Common Stock
2015-04-01$51.68/sh−1,000$51,680→ 48,167 total - Exercise/Conversion
Common Stock
2015-04-01$11.79/sh+4,655$54,882→ 49,167 total - Exercise/Conversion
Option to Purchase Common Stock
2015-04-01−4,655→ 25,345 totalExercise: $11.79Exp: 2023-01-13→ Common Stock (4,655 underlying) - Exercise/Conversion
Common Stock
2015-04-01$6.87/sh+2,845$19,545→ 44,512 total - Sale
Common Stock
2015-04-01$52.29/sh−2,400$125,496→ 45,767 total - Sale
Common Stock
2015-04-01$53.18/sh−4,000$212,720→ 41,767 total - Sale
Common Stock
2015-04-01$54.70/sh−100$5,470→ 41,667 total - Exercise/Conversion
Option to Purchase Common Stock
2015-04-01−2,845→ 7,042 totalExercise: $6.87Exp: 2022-01-18→ Common Stock (2,845 underlying)
Footnotes (8)
- [F1]Includes 5,100 restricted stock units ("RSUs") previously reported as holdings of the Reporting Person granted under the Issuer's 2009 Equity Incentive Plan (the "Plan"). The RSUs will vest, and shares will be delivered to the Reporting Person in a series of three successive annual installments with the next installment occurring on January 2, 2016, provided in each case that the Reporting Person's continuous service to the Issuer has not been terminated as defined in or as determined under the Plan.
- [F2]Includes 7,800 RSUs previously reported as holdings of the Reporting Person granted under the Plan. The RSUs will vest, and shares will be delivered to the Reporting Person in a series of four successive annual installments beginning on January 2, 2016, provided in each case that the Reporting Person's continuous service to the Issuer has not been terminated as defined in or as determined under the Plan.
- [F3]The sales reported in this Form 4 were effected pursuant to a 10b5-1 trading plan adopted by the Reporting Person on 1/5/2015.
- [F4]The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $51.36 to $51.87, inclusive. The reporting person undertakes to provide to the issuer, any security holder of issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each price within the ranges set forth in this footnote to this Form 4.
- [F5]The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $51.95 to $52.73, inclusive. The reporting person undertakes to provide to the issuer, any security holder of issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each price within the ranges set forth in this footnote to this Form 4.
- [F6]The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $52.80 to $53.76, inclusive. The reporting person undertakes to provide to the issuer, any security holder of issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each price within the ranges set forth in this footnote to this Form 4.
- [F7]1/4th of the shares vest on January 18, 2013, which is one year after the vesting commencement date. 1/48th of the shares vest monthly thereafter over the next three years.
- [F8]1/4th of the shares vest on January 14, 2014, which is one year after the vesting commencement date. 1/48th of the shares vest monthly thereafter over the next three years.
Documents
Issuer
NEWLINK GENETICS CORP
CIK 0001126234
Entity typeoperating
IncorporatedDE
Related Parties
1- filerCIK 0001126234
Filing Metadata
- Form type
- 4
- Filed
- Apr 2, 8:00 PM ET
- Accepted
- Apr 3, 5:29 PM ET
- Size
- 19.1 KB